Could a common diabetes pill prevent a Life-Threatening complication?
NCT ID NCT07056699
First seen Nov 11, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This study looks at whether adding pioglitazone (a type 2 diabetes drug) can reduce the harmful side effects of dapagliflozin in people with type 1 diabetes. Dapagliflozin can increase liver glucose, fat breakdown, and ketone production, raising the risk of ketoacidosis. The study will involve 24 adults with type 1 diabetes and poor blood sugar control, measuring changes over 16 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE1DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Texas Diabetes Institute
San Antonio, Texas, 78229-3900, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.